Phase II Trial of Pembrolizumab and Lenvatinib for Leptomeningeal Metastases
Latest Information Update: 19 Mar 2024
At a glance
- Drugs Lenvatinib (Primary) ; Pembrolizumab (Primary)
- Indications Meningeal carcinomatosis; Solid tumours
- Focus Therapeutic Use
- 14 Mar 2024 Status changed from recruiting to discontinued.
- 22 Sep 2021 Status changed from not yet recruiting to recruiting.
- 01 Feb 2021 New trial record